RegulatoryApr 30, 2026, 05:45 PM
TLX: European MAA for TLX101-Px accepted for review
AI Summary
Telix Pharmaceuticals announced that its Marketing Authorization Application (MAA) for TLX101-Px, its glioma (brain cancer) imaging candidate, has been validated and accepted for review in Europe. The application, covering key European markets, has now entered a 210-day active assessment phase, aiming to address the unmet need for consistent, high-quality PET imaging of glioma. This regulatory milestone follows the recent acceptance of TLX101-Px's New Drug Application in the United States, and the company is preparing for market launch in both regions.
Key Highlights
- European Marketing Authorization Application (MAA) for TLX101-Px (glioma imaging candidate) validated and accepted for review.
- The application covers commercially significant European markets and has entered a 210-day active assessment phase.
- Telix aims to expand patient access to advanced brain imaging for distinguishing progressive/recurrent glioma.
- TLX101-Px is also being developed as a patient selection and response assessment tool for TLX101-Tx.
- TLX101-Px's New Drug Application (NDA) has also recently been accepted in the United States.
- The Phase 3 IPAX-BrIGHT trial of TLX101-Tx in recurrent glioblastoma has commenced patient dosing internationally.
- Approximately 67,500 brain and central nervous system tumors are diagnosed annually in Europe.
Price Impact
More from TLX